The Breast Cancer Continuum: Insights from the tamoxifen trials impact future drug development strategies

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 327-332

  Lewis, Jerry P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Invasive and noninvasive breast cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CONFERENCE PAPER; HUMAN; LYMPH NODE METASTASIS; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0035687172     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04040.x     Document Type: Conference Paper

References (6)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
4. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer
5. Bilateral and multifocal breast carcinoma - A clinical and autopsy study with special emphasis on carcinoma in situ: Focal, occult in situ, and invasive carcinoma in 250 mastectomy specimens
6. On the occurrence of focal, occult in situ, and invasive carcinoma in 250 mastectomy specimens